SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Novacare (NOV) breaking out...
NOV 15.67+0.8%Dec 19 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JB Cocallas who wrote (228)2/10/1998 12:57:00 PM
From: Todd D. Wiener  Read Replies (1) of 420
 
Jim-

Although it is a possibility, it doesn't make sense that NCES should be holding back NOV. Then again, the market seldom makes sense. The simple fact that NCES went public makes NOV stock more valuable. Alas, it might require another quarterly report before these stocks take off. Regardless, my 2 year price target is $25 for NOV and $20 for NCES. NCES offers a better return from current prices, but it's also slightly riskier. For every $3 NCES rises in price, NOV should increase in price by $1, based on the value of NCES stock to NOV. So if NCES were to climb to $20, NOV should trade at $17, if only because of its ownership in NCES.

Todd
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext